X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.1872
-0.0141 (-7.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
X4 Pharmaceuticals Stock Forecast
XFOR's stock price has decreased by -84.78% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 2.83, with a low estimate of 1.50 and a high estimate of 4.00. The average target predicts an increase of 1,411.75% from the current stock price of 0.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +701.28% | Mar 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $3 | Buy | Reiterates | $3 | +1,502.56% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +701.28% | Feb 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +701.28% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $1.5 | Strong Buy | Maintains | $5 → $1.5 | +701.28% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
11.65M
from 2.56M
Increased by 355.69%
Revenue Next Year
28.00M
from 11.65M
Increased by 140.28%
EPS This Year
-0.53
from -0.19
EPS Next Year
-0.38
from -0.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1M | 43.1M | 332.5M | ||
| Avg | 11.7M | 28.0M | 122.6M | ||
| Low | 9.6M | 16.1M | 39.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 528.1% | 270.0% | 1,087.8% | ||
| Avg | 355.7% | 140.3% | 337.9% | ||
| Low | 275.6% | 38.2% | 41.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.37 | -0.24 | 0.27 | ||
| Avg | -0.53 | -0.38 | -0.10 | ||
| Low | -0.60 | -0.53 | -0.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.